These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 19266536)

  • 41. Medically assisted reproduction and second-trimester maternal serum marker screening for Down syndrome.
    Muller F; Dreux S; Lemeur A; Sault C; Desgrès J; Bernard MA; Giorgetti C; Lemay C; Mirallié S; Beauchet A;
    Prenat Diagn; 2003 Dec; 23(13):1073-6. PubMed ID: 14691995
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Maternal serum screening for fetal trisomy 18: benefits of patient-specific risk protocol.
    Hogge WA; Fraer L; Melegari T
    Am J Obstet Gynecol; 2001 Aug; 185(2):289-93. PubMed ID: 11518881
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.
    Kagan KO; Anderson JM; Anwandter G; Neksasova K; Nicolaides KH
    Prenat Diagn; 2008 Dec; 28(13):1209-13. PubMed ID: 19039823
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Contingent screening for Down syndrome--results from the FaSTER trial.
    Cuckle HS; Malone FD; Wright D; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Ferreira JC; Dugoff L; Craigo SD; Timor IE; Carr SR; Wolfe HM; D'Alton ME
    Prenat Diagn; 2008 Feb; 28(2):89-94. PubMed ID: 18236423
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Screening for Down syndrome using first-trimester combined screening followed by second trimester ultrasound examination in an unselected population].
    Rozenberg P; Bussières L; Chevret S; Bernard JP; Malagrida L; Cuckle H; Chabry C; Durand-Zaleski I; Bidat L; Lacroix I; Moulis M; Roger M; Jacquemot MC; Bault JP; Boukobza P; Boccara P; Vialat F; Giudicelli Y; Ville Y
    Gynecol Obstet Fertil; 2007 Apr; 35(4):303-11. PubMed ID: 17350315
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The identification of risk of spontaneous fetal loss through second-trimester maternal serum screening.
    Huang T; Owolabi T; Summers AM; Meier C; Wyatt PR
    Am J Obstet Gynecol; 2005 Aug; 193(2):395-403. PubMed ID: 16098861
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hyperglycosylated-hCG (h-hCG) and Down syndrome screening in the first and second trimesters of pregnancy.
    Palomaki GE; Neveux LM; Haddow JE; Wyatt P
    Prenat Diagn; 2007 Sep; 27(9):808-13. PubMed ID: 17590886
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Does vaginal bleeding influence first-trimester markers for Down syndrome?
    Heinig J; Steinhard J; Schmitz R; Nofer JR; Witteler R; Mosel A; Ahrens A; Kiesel L; Klockenbusch W
    Prenat Diagn; 2007 Apr; 27(4):312-6. PubMed ID: 17286311
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elevated maternal second-trimester serum alpha-fetoprotein as a risk factor for placental abruption.
    Tikkanen M; Hämäläinen E; Nuutila M; Paavonen J; Ylikorkala O; Hiilesmaa V
    Prenat Diagn; 2007 Mar; 27(3):240-3. PubMed ID: 17238224
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Screening for Down syndrome using triple marker testing in the second trimester of pregnancy].
    Lesin J; Skrablin S; Durić K; Suchanek E; Muzinić D; Kalafatić D; Kuvacić I; Zlopasa G; Plavec A
    Lijec Vjesn; 2003; 125(3-4):55-60. PubMed ID: 12899094
    [TBL] [Abstract][Full Text] [Related]  

  • 51. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery.
    Spencer K; Cowans NJ; Molina F; Kagan KO; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Feb; 31(2):147-52. PubMed ID: 17992705
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Second-trimester Down syndrome maternal serum marker screening: a prospective study of 11 040 twin pregnancies.
    Garchet-Beaudron A; Dreux S; Leporrier N; Oury JF; Muller F; ;
    Prenat Diagn; 2008 Dec; 28(12):1105-9. PubMed ID: 19003979
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lack of correlation between elevated maternal serum hCG during second-trimester biochemical screening and fetal congenital anomaly.
    Celentano C; Guanciali-Franchi PE; Liberati M; Palka C; Fantasia D; Morizio E; Calabrese G; Stuppia L; Rotmensch S
    Prenat Diagn; 2005 Mar; 25(3):220-4. PubMed ID: 15791663
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus.
    Huttly W; Rudnicka A; Wald NJ
    Prenat Diagn; 2004 Oct; 24(10):804-7. PubMed ID: 15503275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Maternal serum pregnancy-associated plasma protein A (PAPP-A) but not pregnancy-specific beta1-glycoprotein (SP1) is a useful second-trimester marker for fetal trisomy 18.
    Bersinger NA; Leporrier N; Herrou M; Leymarie P
    Prenat Diagn; 1999 Jun; 19(6):537-41. PubMed ID: 10416969
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The variation of risk estimates through pregnancy in second trimester maternal serum screening for Down syndrome.
    Christiansen M; Høgdall EV; Larsen SO; Høgdall C
    Prenat Diagn; 2002 May; 22(5):385-7. PubMed ID: 12001192
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Screening for trisomy 21 in twin pregnancies in the first trimester: an update of the impact of chorionicity on maternal serum markers.
    Spencer K; Kagan KO; Nicolaides KH
    Prenat Diagn; 2008 Jan; 28(1):49-52. PubMed ID: 18186136
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early detection of preeclampsia using inhibin a and other second-trimester serum markers.
    Ree PH; Hahn WB; Chang SW; Jung SH; Kang JH; Cha DH; Kang MS; Huh JY
    Fetal Diagn Ther; 2011; 29(4):280-6. PubMed ID: 21252475
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The detection of non-immune hydrops through second-trimester maternal serum screening.
    Saller DN; Canick JA; Oyer CE
    Prenat Diagn; 1996 May; 16(5):431-5. PubMed ID: 8844001
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of the combined first-trimester screen result and low PAPP-A to predict risk of adverse fetal outcomes.
    Barrett SL; Bower C; Hadlow NC
    Prenat Diagn; 2008 Jan; 28(1):28-35. PubMed ID: 18186146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.